FDA, Capricor and Priority Review
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
"Zevra sells priority review voucher for $150m to support drug launches" was originally created and published by ...
Emapalumab-Izsg is under the FDA’s Priority Review for hemophagocytic lymphohistiocytosis/macrophage activation syndrome in Still disease.
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Priority Gold makes acquiring precious metals ... This is reflected in the company’s positive reviews across multiple independent platforms. This includes an A+ rating from the Better Business ...
The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for deramiocel (CAP-1002) for the treatment ...
The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...
FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback